

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:52:43 ON 14 JAN 2003

=> file .jacob

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 13:52:54 ON 14 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:52:54 ON 14 JAN 2003

FILE 'EMBASE' ENTERED AT 13:52:54 ON 14 JAN 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:52:54 ON 14 JAN 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s insulin near5 purification

L1 0 FILE CAPLUS

L2 0 FILE MEDLINE

L3 0 FILE EMBASE

L4 0 FILE BIOSIS

TOTAL FOR ALL FILES

L5 0 INSULIN NEAR5 PURIFICATION

=> s insulin near 4 purification

L6 0 FILE CAPLUS

L7 0 FILE MEDLINE

L8 0 FILE EMBASE

L9 0 FILE BIOSIS

TOTAL FOR ALL FILES

L10 0 INSULIN NEAR 4 PURIFICATION

=> s insulin adj4 purification

L11 0 FILE CAPLUS

L12 0 FILE MEDLINE

L13 0 FILE EMBASE

L14 0 FILE BIOSIS

TOTAL FOR ALL FILES

L15 0 INSULIN ADJ4 PURIFICATION

=> s purification adj2 insulin

L16 0 FILE CAPLUS
L17 0 FILE MEDLINE
L18 0 FILE EMBASE
L19 0 FILE BIOSIS

TOTAL FOR ALL FILES

L20 0 PURIFICATION ADJ2 INSULIN

=> s insulin and purification

L21 2092 FILE CAPLUS
L22 4928 FILE MEDLINE
L23 1482 FILE EMBASE
L24 1539 FILE BIOSIS

TOTAL FOR ALL FILES

L25 10041 INSULIN AND PURIFICATION

=> s l25 and antibody

L26 320 FILE CAPLUS
L27 901 FILE MEDLINE
L28 254 FILE EMBASE
L29 212 FILE BIOSIS

TOTAL FOR ALL FILES

L30 1687 L25 AND ANTIBODY

=> s l30 and impurity

L31 4 FILE CAPLUS
L32 1 FILE MEDLINE
L33 2 FILE EMBASE
L34 0 FILE BIOSIS

TOTAL FOR ALL FILES

L35 7 L30 AND IMPURITY

=> dup rem

ENTER L# LIST OR (END):L35

PROCESSING COMPLETED FOR L35

L36 6 DUP REM L35 (1 DUPLICATE REMOVED)

=> d l36 ibib abs total

L36 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:386308 CAPLUS

DOCUMENT NUMBER: 133:140041

TITLE: Isolation, properties and immunoaffinity
chromatography of proinsulin **impurities** in
commercial porcine **insulin** preparations

AUTHOR(S): Moroz, I. N.; Ermolenko, M. N.; Pryadko, A. G.;
Levchenko, V. K.; Senchuk, Yu. V.; Svirid, V. D.;
Sviridova, O. V.; Didorenko, A. I.; Petrov, P. T.;
Tsarenkov, V. M.

CORPORATE SOURCE: Inst. Bioorg. Khim., NAN Belarusi, Belarus

SOURCE: Vestsi Natsyyanal'nai Akademii Navuk Belarusi, Seryya
Khimichnykh Navuk (2000), (1), 72-78
CODEN: VNBNFX; ISSN: 1561-8331

PUBLISHER: Belaruskaya Navuka

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Porcine proinsulin has been isolated from a secondary fraction of the
industrial process of **insulin purifn.** The native
prohormone and its damaged mol. form with the cleavaged Arg63-Gly64 bond
prevailed in the isolated prepn. According to the quality gradation

accepted in immunoassay technol., the purified proinsulin met the following requirements: suitable for labeling, immunization and std. prepn. Murine monoclonal **antibodies** to proinsulin have been obtained and characterized. A purified product' of one of the clones was immobilized on CNBr-activated Sepharose. An interaction of the isolated proinsulin and the prohormone in **insulin** fractions with the immunoaffinity column has been studied. In principle, the possibility was shown for contaminant proinsulin to be completely removed from com. **insulin** prepn. by immunoaffinity chromatog.

L36 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1988:62416 CAPLUS
DOCUMENT NUMBER: 108:62416
TITLE: Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
INVENTOR(S): Chandra, Sudhish; Feldman, Fred
PATENT ASSIGNEE(S): Armour Pharmaceutical Co., USA
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 197554	A2	19861015	EP 1986-104849	19860409
EP 197554	A3	19870325		
EP 197554	B1	19900725		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4673733	A	19870616	US 1985-722561	19850411
AU 8655960	A1	19861106	AU 1986-55960	19860409
AU 580402	B2	19890112		
CA 1262682	A1	19891107	CA 1986-506180	19860409
AT 54828	E	19900815	AT 1986-104849	19860409
DK 8601617	A	19861012	DK 1986-1617	19860410
JP 61275210	A2	19861205	JP 1986-82425	19860411
JP 05078532	B4	19931029		

PRIORITY APPLN. INFO.: US 1985-722561 19850411
EP 1986-104849 19860409

AB Viruses and pyrogens in pharmaceutical products are inactivated by adsorbing the product onto a solid phase, which is washed with a virus deactivating or depyrogenating agent. **Impurities** and residual wash are removed from the solid phase, and the product is recovered. Blood products may thus be freed of hepatitis B virus. The plasma fraction used for isolating prothrombin complex was spiked with Sindbi's or vesicular stomatitis virus (VSV). The plasma was absorbed onto DEAE-Sephadex and treated with 2% Triton X-100 to inactivate the virus. The ion exchanger was washed with a citrate buffer and the prothrombin complex was eluted. In a control, the Triton X-100 wash was not used! The Triton X-100 treatment decreased virus activities of Sindbis and VSV by 2.07 .times. 103 and 8.45 .times. 104 times compared to controls, in vitro.

L36 ANSWER 3 OF 6 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 81036331 EMBASE
DOCUMENT NUMBER: 1981036331
TITLE: The immunogenicity of **insulin** preparation.
Antibody levels before and after transfer to highly purified porcine **insulin**.
AUTHOR: Heding L.G.; Larsson Y.; Ludvigsson J.
CORPORATE SOURCE: Novo Res. Inst., DK-2880 Bags Vaerd, Denmark
SOURCE: Diabetologia, (1980) 19/6 (511-515).

COUNTRY: Germany
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
006 Internal Medicine
026 Immunology, Serology and Transplantation
030 Pharmacology
LANGUAGE: English

AB Ninety-two **insulin**-dependent diabetics (aged 4-20 years, mean \pm SD: 13 \pm 4) with a duration of diabetes from 2 to 17 years (7 \pm 3) were transferred from Lente or NPH (5 x crystallised **insulin**) to Monotard **insulin** (highly purified **insulin**). Total serum immunoreactive **insulin** levels and concentrations of **antibodies** against **insulin**, porcine proinsulin, a-component and pancreatic polypeptide were determined prior to [I] and at a mean of 220 [II], 460 [III], 830 [IV], and 1170 [V] days after the change. All but two subjects had **insulin antibodies** (IgG) at the start, with a mean value of 2864 μ U/ml. There was a significant fall in the mean **insulin antibody** level between [I] and [II] to 2165 μ U/ml ($p < 10^{-7}$), followed by an increase between [II] and [III] whereafter a slight decrease was observed being significant between [III] and [IV], as well as between [IV] and [V] ($p < 0.05$); some patients showed a constant fall over the entire period, while others showed fluctuations. Total serum **insulin** showed a similar pattern, with a mean value of 1141 μ U/ml at [I] declining to 522 μ U/ml at [V]. The percentage fall between [I] and [V] was greater (54%) than that in the **insulin antibodies** (30%). **Antibodies** against a-component, proinsulin and pancreatic polypeptide were present in 96%, 72% and 41% of the patients respectively before the change in therapy. There was a decline in these **antibodies** between each sampling (p values between $< 10^{-3}$ and 10^{-8}) and, at the end of the investigation **antibodies** against a-component were above the detection limit in only 4 patients, and none of the patients showed **antibodies** against proinsulin or pancreatic polypeptide. Thus, removal of the **impurities**, including the hormonal contaminants of **insulin**, leads to a slow fall in **antibodies** to **insulin** and a much faster disappearance of **antibodies** against a-component, proinsulin and pancreatic polypeptide.

L36 ANSWER 4 OF 6 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 79014681 MEDLINE
DOCUMENT NUMBER: 79014681 PubMed ID: 694712
TITLE: Circulating **antibodies** in diabetics treated with conventional and purified **insulins**.
AUTHOR: Klaff L J; Vinik A I; Berelowitz M; Jackson W P
SOURCE: SOUTH AFRICAN MEDICAL JOURNAL, (1978 Jul 22) 54 (4) 149-53.
Journal code: 0404520. ISSN: 0038-2469.
PUB. COUNTRY: South Africa
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197812
ENTRY DATE: Entered STN: 19900314
Last Updated on STN: 19900314
Entered Medline: 19781202

AB Conventional **insulins** contain **impurities** which are immunogenic; these include pancreatic polypeptide (PP), glucagon and somatostatin and intermediates of **insulin** synthesis co-extracted during **purification**. Monocomponent (MC) **insulins** are free of these contaminants. In 49 **insulin**-treated diabetic patients, **antibodies** were found to **insulin** (94%), pro-**insulin** (68%) and PP (68%). **Antibodies** to glucagon and somatostatin were not detected. There was a significantly lower mean

maximum binding and titre of **insulin** and PP **antibodies** and total circulating **insulin** (i.e. **antibody** bound and free) in patients receiving MC **insulin**. In patients treated with MC **insulins** for longer than 2 years there was a significant fall in the mean maximum binding of **insulin** and total serum **insulin**, but no consistent change in diabetes control and daily **insulin** dose. It seems that except in the special instances of fat atrophy, **insulin** allergy and certain cases of **insulin** resistance, there is no need to resort to MC **insulin**.

L36 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1977:562071 CAPLUS

DOCUMENT NUMBER: 87:162071

TITLE: Monocomponent **insulin** and its clinical implications

AUTHOR(S): Schlichtkrull, J.; Brange, J.; Christiansen, A. H.; Hallund, O.; Heding, L. G.; Joergensen, K. H.; Rasmussen, S. Munkgaard; Soerensen, E.; Voelund, A.

CORPORATE SOURCE: Novo Res. Inst., Copenhagen, Den.

SOURCE: Hormone and Metabolic Research, Supplement Series (1974), 5(Radioimmunoassay: Methodol. Appl. Physiol. Clin. Stud.), 134-43

CODEN: HMMSAU; ISSN: 0170-5903

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Conventional **insulin** [9004-10-8] contains varying amts. of contaminating pancreatic proteins which induced **insulin antibodies** in rabbits. These proteins were fractionated and possess proinsulin [9035-68-1] and **insulin**-like immunogenic sites. In patients, conventional mixed-species **insulin** preps. also induced **antibodies** against non-**insulin**-like antigenic sites present in bovine a-component. Such **antibodies** were not found in patients treated with the same mixed-species preps. freed from the high-mol.-wt. contaminants. Purifn. of pork **insulin** by gel filtration chromatog. in comparison with recrystns. did not result in lower immunogenicity in rabbits whereas the monocomponent (MC-) **insulin** (pork) showed little or no immunogenicity under the same conditions. Three groups of patients who never had received **insulin** were treated, resp., with conventional Lente (mixed beef/pork), pork Lente of com. grade, and Mono-tard, i.e., Lente made of pork MC-**insulin**. The **insulin antibody** levels were followed for about 2 years. Conventional Lente (mixed species) was more immunogenic than the porcine variety. The latter induced significant amts. of **insulin antibodies** in comparison to the monocomponent pork **insulin**, which had little or no immunogenicity, demonstrating the significance of the impurities.

L36 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1974:22967 CAPLUS

DOCUMENT NUMBER: 80:22967

TITLE: Glomerular basement membrane of the rabbit kidney on long-term treatment with heterologous **insulin** preparations of different purity

AUTHOR(S): Wehner, H.; Huber, H.; Kronenberg, K. H.

CORPORATE SOURCE: Inst. Pathol., Univ. Tuebingen, Tuebingen, Fed. Rep. Ger.

SOURCE: Diabetologia (1973), 9(4), 255-63

CODEN: DBTGAJ; ISSN: 0012-186X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In rabbits treated 1, 2, 3 or 10 mo. with a highly purified monocomponent **insulin** [9004-10-8] (20 units, 3 times weekly, s.c.), there was no alteration of **antibody** formation and no increased occurrence of

kidney subepithelial basement membrane protuberances. In contrast, administration of **insulin impurities** (high-mol. wt. proteins, proinsulin, **insulin** dimer and intermediates), obtained on **purifn.** of **insulin**, increased the **antibody** titer and induced nodular basement membrane changes in the glomeruli. The high antigenicity of com. available **insulin** preps. may be due to the presence of **impurities**.